← Back to Search

Monoclonal Antibodies

UTTR1147A for Crohn's Disease

Phase 2
Waitlist Available
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new medication called UTTR1147A to see if it is safe and can be tolerated over a long period. It focuses on people with moderate to severe ulcerative colitis or Crohn's disease. The goal is to find a treatment that can help manage symptoms and improve their quality of life.

Eligible Conditions
  • Colitis
  • Crohn's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Number of Participants With Adverse Events

Side effects data

From 2021 Phase 2 trial • 396 Patients • NCT04386616
8%
Constipation
7%
Anaemia
7%
Hypokalaemia
6%
Hypertension
5%
Headache
5%
COVID-19 pneumonia
5%
Hypotension
4%
Anxiety
3%
Dry skin
3%
Respiratory failure
2%
Pneumothorax
2%
Nausea
2%
Multiple organ dysfunction syndrome
2%
Acute kidney injury
2%
Hypoxia
2%
Atrial fibrillation
2%
Pneumonia
2%
Gastric ulcer haemorrhage
2%
Acute myocardial infarction
2%
COVID-19
2%
Septic shock
1%
Renal impairment
1%
Pneumonia aspiration
1%
Urinary tract infection
1%
Pneumomediastinum
1%
Shock haemorrhagic
1%
Urosepsis
1%
Liver injury
1%
Shock
1%
Confusional state
1%
Respiratory arrest
1%
Cardiac failure
1%
Toxic encephalopathy
1%
Aspartate aminotransferase increased
1%
Pulmonary embolism
1%
Pneumonia bacterial
1%
Haematuria
1%
Left ventricular failure
1%
Cardiac arrest
1%
Pleural effusion
1%
Right ventricular dysfunction
1%
Uterine leiomyoma
1%
Respiratory distress
1%
Radius fracture
1%
Oxygen saturation decreased
1%
Hypernatraemia
1%
Acute respiratory failure
100%
80%
60%
40%
20%
0%
Study treatment Arm
All Placebo
MSTT1041A
UTTR1147A

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: UTTR1147AExperimental Treatment1 Intervention
All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
UTTR1147A
2018
Completed Phase 2
~740

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,559 Previous Clinical Trials
569,311 Total Patients Enrolled
Clinical TrialsStudy DirectorHoffmann-La Roche
2,226 Previous Clinical Trials
896,235 Total Patients Enrolled
~21 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top